trustworthy poultry - ceva egypt · trustworthy poultry cevac ... infectious coryza is a widely...

CEVAC® CORYMUNE RANGE - 1

TRUSTWORTHYPOULTRYPOULTRY

CEVAC® CORYMUNE RANGE Unique combination vaccines to protect against Coryza and Salmonella

Supported by

CEVAC® CORYMUNE RANGE CEVAC® CORYMUNE 4K• Unique broad combination vaccine

against Infectious Coryza and Salmonella• Mild adjuvant to optimize bodyweight

development • Suitable for early vaccination

CEVAC® CORYMUNE 7K• Unique broad combination vaccine for protection

against infectious Coryza, Salmonella, ND, IB and EDS• Simplifi es the vaccination schedule and includes

salmonella protection• Broad Salmonella and infectious Coryza protection• Booster adjuvant for long lasting immunity

216x279-CEVA-BROCHURE CORYMUNE2.indd 1 22/04/13 11:39

2- CEVAC® CORYMUNE RANGE

Unique combination vaccines to protect against Coryza, Salmonella, ND, IB and EDS

CEVAC® CORYMUNE RANGE

The increase of more concentrated fl ocks due to the rapid growth of global poultry production has led to increased exposure and pathogen spread. Layer and breeder farms battle pathogens that commonly include Infectious Coryza (IC), Newcastle disease (ND), Infectious Bronchitis (IB), and Egg drop syndrome (EDS). Producers must control Salmonella bacteria before it affects bird health (SalmonellaGallinarum) and spreads food borne diseases in humans. In the majority of people infected by Salmonella Enteridis, contamination can be traced back to eggs or poultry meat, leading to an immediate loss of trust in, and economic impact on, both the poultry producers and the industry as a whole.

While vaccination has proven to be a very effective tool to control these diseases, the stress incurred with multiple vaccinations can cause growth delay, loss in fl ock uniformity, and eventually lower egg production.

In response, Ceva has developed a unique broad combination range of vaccines to control these major diseases while also controlling the risk of poultry, egg and meat Salmonella contamination by Salmonella Enteritidis and Salmonella Gallinarum.



UNIQUE COMBINATION VACCINES FOR PROTECTIONAGAINST THE MAJOR POULTRY DISEASES

CEVAC® CORYMUNE 4K• Broad Infectious Coryza protection

• Serovars A, B and C • Salmonella Entertidis protection• Mild adjuvant suitable for early vaccination• No extra vaccinations needed for Salmonella protection

CEVAC® CORYMUNE 7K• Broad Infectious Coryza protection

• Serovars A, B and C • Salmonella Entertidis protection• Cross protection against Salmonella Gallinarum• Booster adjuvant suitable for prolonged immunity• Strong, long-lasting immunity for IB, ND and EDS*

• No extra vaccinations needed for Salmonella protection

CEVA EGGS PROGRAM: SAFER & SIMPLER VACCINATIONCeva’s EGGS Program is a comprehensive package of services and Standard Operating Procedures (SOPs) designed to optimize the preparation, application and monitoring of poultry vaccines.

Unique equipment like the Desvac IMVAC® has been developed to achieve precise injection of vaccines into the breast muscle of each bird while ensuring safety for both the bird and operator.

*Following live priming for IB and ND

Unique combination vaccines to protect against Coryza, Salmonella, ND, IB and EDS

Supported by



SALMONELLA MAJOR CAUSE OF FOOD BORNE DISEASES. Human Salmonella is a major cause of food borne illness around the world. In many cases, human infection traces back to poultry meat or eggs, with Salmonella Enteritidis the main serovar found. Salmonella Enteritidis can infect the ovaries of a bird and the egg before the shell is formed. Birds positive for Salmonella spread the bacteria to other birds via manure and dust. In the past, the increase of human Salmonellosis linked to egg contamination in the UK (1988) and more recently in the US (2010) had a huge negative impact on the image of the poultry industry and producers. Controlling Salmonella is not easy; vaccination is a key part of a well-designed control plan that must be in place. The use of Salmonella vaccines have proven to be very effi cacious in reducing the risk of Salmonella spreading between fl ocks (horizontal) and, in case of inactivated vaccines, in reducing the risk from breeders to progeny (vertical). This effectiveness is the reason that Salmonella vaccines are used successfully in the European Union,US and in other parts of the world.

REDUCTION OF SHEDDING OF SALMONELLA ENTERITIDIS1

In this trial, Salmonella-negative commercial pullets were divided in two groups. The vaccinated group received Cevac® Corymune 4K at 11 weeks and Cevac® Corymune 7K at 15 weeks. The control group did not receive any Salmonella vaccine.At week 39, a massive oral challenge (1010 CFU/bird, 1 ml) was given. External shedding of the challenge strain was measured at 4 and 10 days post challenge.

Vaccinated group Control group

4 days post challengeCaecal content Non quantifi able 105

Faeces Non quantifi able 107

10 days post challenge Faeces Non quantifi able 106

CONCLUSION

Vaccination with Cevac® Corymune 4K & Cevac® Corymune 7K induced a 100,000 to 10 million times reduction factor in the amount of Salmonella Enteritidis spread, reducing the risk of spreading of Salmo-nella in the environment and between fl ocks.



CROSS PROTECTION AGAINST SALMONELLA GALLINARUM2 In an independent laboratory, commercial brown layer pullets were vaccinated with Cevac® Corymune 4K at 5 weeks and revaccinated with Cevac® Corymune 7K at 9 weeks of age. Another group served as a control group.

At 12 weeks of age the birds were challenged with a massive amount of Salmonella Gallinarum by oral route.The mortality of the birds was monitored during 4 weeks post vaccination. The results are listed below.

35

26a

2b

12b 12b 12b

31a 31a 31a30

25

No

of b

irds

20

15

10

5

01 2 3 4

Cumulative mortality after SG challenge

*Letter with different subscript indicates signifi cant difference

Corymune group Non vaccinated control

CONCLUSION

Vaccination with Cevac® Corymune 4K & Cevac® Corymune 7K signifi cantly reduced mortality after a strong Salmonella Gallinarum challenge, proving Cevac’s Corymune strong cross protection against Salmonella Gallinarum



INFECTIOUS CORYZAInfectious Coryza is a widely recognized and commonly found respiratory disease caused by Avibacteriumparagallinarum. The disease is global, but major cases found in the southern hemisphere cause economic losses due to increased mortality, severe decline of egg production (to over 40%) or decline in bodyweight development.Symptoms include nasal discharge, swollen sinuses, watery eyes, facial oedema, diffi culty breathing and drop in egg production. According to the Page classifi cation, 3 serovars of Avibacterium paragalllinarum are potentially involved. Serovar A, B and C, all are described as causing clinical signs. Vaccination combined with good biosecurity has proven to be very effi cacious in controlling Infectious Coryza.

Cevac®Corymune 4K & Cevac®Corymune 7K contain the serovars, A, B and C of Avibacterium paragallinarum, offering a broad infectious Coryza protection.



CEVAC® CORYMUNE 4K & CEVAC®

CORYMUNE 7K TRIAL RESULTS3

In a trial carried out using commercial brown layer pullets, the birds were divided into a vaccinated and a control group. The vaccinated group received Cevac® Corymune 4K at 11 weeks followed by a boostervaccination with Cevac® Corymune 7K at 15 weeks. Both groups were challenged at 20 weeks, 35 weeksand 55 weeks with high doses of virulent Avibacterium paragallinarum, serovar A, B and C.

The clinical signs of Coryza were then monitored for 1 week post challenge.

Prot

ectio

n ra

te (%

)

0A B C

10

203040

50

60

708090

100

Infectious Coryza challenge(20 weeks) in commercial pullets

vaccinated using Cevac® Corymune4 K and Cevac® Corymune 7 K

Challenge serotype Controls vaccinated

Prot

ectio

n ra

te (%

)

0A B C

10

20

30

4050

60

708090

100

Infectious Coryza challenge(35 weeks) in commercial pullets vaccinated using

Cevac® Corymune 4 K and Cevac® Corymune 7 K


Prot

ectio

n ra

te (%

)

0A B C

10

20

30

4050

60

708090

100

Infectious Coryza challenge (55 weeks) in commercial pullets vaccinated using Cevac® Corymune

4 K and Cevac® Corymune 7 K


CONCLUSION

Cevac® Corymune 4K & Cevac® Corymune 7K provides good clinical protection at 20, 35 and 55 weeks of age against serovar A, B and C after a severe Infectious Coryza challenge.



NEWCASTLE DISEASE VIRUS (NDV)Newcastle disease, due to avian paramyxovirus, is one of the most devastating diseases in poultry, and in many countries remains a major risk for the poultry industry. Control of NDV is ensured by biosecurity and a well-designed vaccination program. Clinical and economic losses are due to respiratory problems, lameness, declines in eggproduction and high mortality. According to several regulations, outbreaks of Newcastle Disease virus immediately effects export business.

NEWCASTLE DISEASE PROTECTION OF CEVAC® CORYMUNE 7K4

Commerical brown pullets were split in two groups and used to check the protection of Cevac® Corymune 7K and the commercial reference inactivated vaccine (ND, IB EDS) against a velogenic viscerotropic NDV (Herts) strain challenge at 40 weeks. Both groups received three live vaccines during the rearing period. Cevac® Corymune 7K or the reference vaccine were applied at 15 weeks by intramuscular route. There were two non-vaccinated control groups, one commercial group and one group with SPF birds. The results of the challenge are displayed below.

Prot

ectio

n ra

te (%

)

0L + Corymune L + ND IB EDS K Controls (commercial) Controls (SPF)

10

20

30

40

50

60

70

80

90

100

Cevac Corymune 7 K: effi cacy of its booster effect against a ND challengeat 40 weeks of age

*51 weeks was shown in other trial, results available on request.

production and high mortality. According to several regulations, outbreaks of Newcastle Disease virus immediately effects export business.

NEWCASTLE DISEASE PROTECTION OF CEVAC

production and high mortality. According to several regulations, outbreaks of Newcastle Disease virus immediately

NEWCASTLE DISEASE PROTECTION OF CEVAC® CORYMUNE 7K4

production and high mortality. According to several regulations, outbreaks of Newcastle Disease virus immediately

NEWCASTLE DISEASE PROTECTION OF CEVAC

CONCLUSION

Cevac® Corymune 7K protects against a strong NDV challenge and effi cacy was shown to at least51 weeks of age*. This protection is similar to a basic ND, IB EDS inactivated vaccine.



INFECTIOUS BRONCHITIS VIRUS (IBV)Infectious Bronchitis virus (IBV), due to a Coronavirus, is a disease with major economic impact. IBV is an acute, highly contagious viral respiratory disease of chickens characterized by tracheal rales, coughing, and sneezing. The disease can also affect the kidneys or the ovary system. In egg layers and breeders IBV causes a severe decline in egg production,poor egg shell quality, birds not developing a proper ovary system (false layers), wet litter and a variety of other clinical signs.

The severity of egg production decline depends on the virulence of the virus and other non-specifi c factors. Egg productionmay improve after 2-3 weeks but reaches only sub-optimal levels and can cause soft-shelled eggs or misshapen eggs.may improve after 2-3 weeks but reaches only sub-optimal levels and can cause soft-shelled eggs or misshapen eggs.

EFFICACY OF CEVAC®CORYMUNE 7K AGAINST AN IB CHALLENGEIn this trial commercial brown layer pullets were used; the two vaccinated groups received 3 live IB vaccines (Mass type) and Cevac® Corymune 7K or a basic ND, IB EDS combination vaccine as inactivated booster vaccine. The control group was not vaccinated for IB.At week 29 all groups received an IB challenge (M41 strain) by intra-tracheal route. All groups were observed for10 weeks post-challenge on production effects and clinical signs; the results are displayed below.

Ave

rage

wee

kly

egg

pro

duct

ion

(%)

020

10

20

30

40

50

60

70

80

90

100

21 22 23 24 25 26 27 28 29

IBchallenge

*

30 31 32 33 34 35 36 37 38 39

Cevac Corymune 7 K effi cacy against IB challenge at 29 weeks of age

Age (weeks) L+ Corymune, ch L+ NDIBEDS, ch no IB vacc, ch

CONCLUSION

Cevac® Corymune 7K provided signifi cant protection against production drops caused by IB challenge and protection was similar to reference vaccine consisting of IB, ND & EDS at 29 weeks of age.



EGG DROP SYNDROME (EDS) EDS, which is caused by an adenovirus, is an important disease affecting laying hens. Egg drop syndrome strongly affects egg production and results in loss of color for brown eggs, quickly followed by production of thin-shell eggs, soft-shell eggs or shell-less eggs. The drop in egg production can be very rapid and extend over weeks. Outbreaks usually last 4-10 weeks and egg production can decline up to 40%. Birds of all ages in production of all ages are sus-ceptible, making long-lasting immunity important.ceptible, making long-lasting immunity important.

EFFICACY OF CEVAC® CORYMUNE AGAINST EDS6

In a trial using commercial layer pullets, birds were split up in three groups. One group was vaccinated with Cevac® Corymune 4K at week 12& Cevac® Corymune 7K at 15 weeks; the other two groups served as challenged non vaccinatedcontrols and unchallenged vaccinated control groups.

At week 40 a heterlogous challenge (Mc Ferran strain) was applied to the birds. 4 weeks post-challenge the production was observed for 4 weeks. Production data is shown below.

Ave

rage

wee

kly

egg

pro

duct

ion

(%)

038 39 40 41 42 43

10

20

30

4050

60

708090

100

EDSchallenge

Cevac Corymune 7 K effi cacy against EDS chal-lenge at 40 weeks of age

Age (weeks)

C

CONCLUSION

Cevac® Corymune 7 provided strong protection against Egg drop syndrome untilat least 41 weeks of age.

Cevac C4K + C7K Challenged controls Unchallenged CK + C7K


CEVAC® CORYMUNE RANGE - 11CEVAC® CORYMUNE RANGE - 11CEVAC® CORYMUNE RANGE - 11

SAFETY PROFILE OF CEVAC® CORYMUNE 4K ANDCEVAC® CORYMUNE 7K

The best way to ensure proper long-lasting protection resulting in good egg production is to use an inactivated vaccine containing mineral oil as adjuvant, as Cevac® Corymune 7K is designed. Mineral oil used as adjuvant can cause local tolerance issues when injected to the bird. Great care was taken to ensure perfect tolerance of Cevac® Corymune 4K and Cevac® Corymune 7K has an Aluminium hydroxide as adjuvant for use in younger birds.

FIELD TRIALIn a fi eld trial two fl ocks were compared for bodyweight development after vaccination with inactivated vaccines.

The Cevac® Corymune vaccinated fl ock was vaccinated at week 12 with Cevac® Corymune 4K followed by Cevac® Corymune 7K at 16 weeks. The control fl ock received a standard Coryza vaccine at week 12 followed by a Coryza and a ND IB EDS inactivated vaccine at week 16. All vaccines were applied through intra muscular route. The bodyweight was measured weekly from week 11 to week 24 and is shown below.

Body

wei

ght i

n gr

am

0

900

1100

1300

1500

1700

1900

11 wks 12 wks 13 wks 14 wks 15 wks 16 wks 17 wks 18 wks 19 wks 20 wks 21 wks 22 wks 23 wks 24 wks

1st v

accin

atio

n 2nd

vacc

inat

ion

Bodyweight development (g) aftervaccination with Cevac Corymune

CONCLUSION

Cevac® Corymune 4K & Cevac® Corymune 7K have an excellent safety profi le, the vaccines did not infl uence bodyweight development comparined to pullets receiving a placebo or receiving a monovalentCoryza or Coryza combination vaccine.

Average Weight (control group) Average Weight (Cevac Corymune group)


RECOMMENDED VACCINATION SCHEDULE

1st application(8-12 weeks of age)*

Booster application between2 to 4 weeks before onsetof production 14 to 18 weeks of age*

Administration and dosage

Cevac® Corymune 4K Cevac® Corymune 7K

Intramuscular route (breast muscles) or subcutaneously route (under the skin of the neck).0.5 ml per bird

*Flexible regarding the epidemiological fi eld situation

CEVAC® CORYMUNE 4K AND CEVAC® CORYMUNE 7K • Convenience by combining protection against Salmonella, Infectious Coryza, ND, IB and

EDS to reduce the number of bird handlings

• Broad protection against Salmonella Enteritidis and Salmonella Gallinarum

• Strong, long-lasting immunity against ND, IB and EDS

• Clinical protection against the 3 serovars - A, B and C - of Infectious Coryza

• No extra vaccinations needed to protect against Salmonella, which protects both your poultry AND your company’s reputation

1: R062, report REG-024-20092: Penha Filho R.A.C. et al., Avian Pathology 2009, 38(5), 367-3753: R062, report REG-104-20084: Reg. fi le C606.4.00.E.1 Oct.5: R062, report REG-106-20086: Registration fi le C606.4.00.E.1 Oct. 2006

COMPOSITION: CEVAC® CORYMUNE 4K contains an inactivated combination of Avibacterium paragallinarum, serovars A, B and C and Salmonella Enteritidis strain, homogenized with aluminum hydroxyde and thiomersal as a preservative.-INDICATION: CEVAC® CORYMUNE 4K is recommended for the active immunization of breeder and laying-type chickens fl ocks against infectious coryza caused by Avibacterium paragallinarum and Salmonella Enteritidis infection. The program should be completed 4 to 6 weeks later, using an oil-adjuvant inactivated vaccine against the same diseases.-ADMINISTRATION and DOSAGE: CEVAC® CORYMUNE 4K should be administered to breeder and laying-type pullets, between 8 to 12 weeks of age. The vaccine must be injected subcutaneously (under the skin of the neck) or by intramuscular route (breast or thigh muscles) at the dose of 0,5ml per bird.- GENERAL PRECAUTIONS: Satisfactory protection can be achieved in well-developed, healthy birds only. Use sterile injection equipment. Keep the vaccine at room temperature (15 to 25°C) for 3 to 4 hours before use. Shake the bottle well before and during use. Check the accuracy of the syringe to ensure that the correct dose is delivered. Once a bottle has been opened, its content must be used up within 24 hours; otherwise, it should be discarded.-WARNING: Do not mix the vaccine with others vaccines or pharmaceutical products. If the vaccine is accidentally injected to the operator, urgent medical attention is required.-STORAGE: Between 2°C and 8°C, protected from light.Do not freeze.

COMPOSITION: CEVAC® CORYMUNE 7K contains an inactivated combination of Avibacterium paragallinarum, serovars A, B and C, Salmonella Enteritidis strain, La Sota strain of Newcastle disease virus, Massachussetts strain of infectious bronchitis virus and B8/78 strain of the EDS virus, homogenized with oil adjuvant and thiomersal as a preservative.- INDICATION: CEVAC® CORYMUNE 7K is recommended for the active immunization of breeder and laying-type chickens fl ocks against infectious coryza caused by Avibacterium paragallinarum, Salmonella Enteritidis infection, Newcastle disease, infectious bronchitis and egg drop syndrom’76.The birds should be previously immunized with live vaccines against. Newcastle diseases and infectious bronchitis and 4 to 6 weeks before, with an inactivated vaccine against infectious coryza and Salmonella Enteritidis infection.-ADMINISTRATION and DOSAGE: CEVAC® CORYMUNE 7K should be administered to breeder and laying-type pullets, 2 to 4 weeks before the onset of lay, between 14 to 18 weeks of age. The vaccine must be injected subcutaneously (under the skin of the neck) or by intramuscular route (breast muscles) at the dose of 0,5ml per bird.-GENERAL PRECAUTIONS: Satisfactory protection can be achieved in well-developed, healthy birds only. Use sterile injection equipment. Keep the vaccine at room temperature (15 to 250C) for 3 to 4 hours before use. Shake the bottle well before and during use. Check the accuracy of the syringe to ensure that the correct dose is delivered. Once a bottle has been opened, its content must be used up within 24 hours; otherwise, it should be discarded.-WARNING: Do not mix the vaccine with others vaccines or pharmaceutical products. If the vaccine is accidentally injected to the operator, urgent medical attention is required.-STORAGE: Between 2°C and 8°C, protected from light. Do not freeze.

Ceva Santé Animale S.A. / www.ceva.com / [email protected]


trustworthy poultry - ceva egypt · trustworthy poultry cevac ... infectious coryza is a widely...

Documents